Larotinib treatment for advanced esophageal cancer

Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study

This study is testing if a new drug called Larotinib can help people with advanced esophageal cancer who haven't had success with other treatments.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 416 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Sunshine Lake Pharma Co., Ltd. (Industry-sponsored)
• Drugs / interventions: immunotherapy, radiation, Larotinib, chemotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT04415853 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy of Larotinib in patients with unresectable advanced or recurrent esophageal squamous cell carcinoma who have failed at least two lines of standard therapy and exhibit EGFR overexpression. Participants are randomly assigned to receive either Larotinib or a chemotherapy regimen chosen by the investigator, with treatment continuing until disease progression or unacceptable toxicity occurs. The study includes a screening period, treatment period, and follow-up for safety and survival outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with confirmed advanced esophageal squamous cell carcinoma and documented disease progression after prior therapies.

Not a fit: Patients who have previously received EGFR-targeted therapies or have other contraindications may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced esophageal cancer who have limited treatment alternatives.

How similar studies have performed: While there have been studies on EGFR-targeted therapies, the specific use of Larotinib in this context is novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Age:18-75 years, male or female.
2. Histologically or cytologically confirmed squamous cell carcinoma of the esophagus or advanced/metastatic disease.
3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Life expectancy of greater than 3 months.
5. Documented objective radiographic or clinical disease progression on two previous lines of standard therapy.
6. Can provide archival tumor tissue sample for biomarker analysis (such as EGFR overexpression/expansion status), biopsies are required if tissue samples cannot be provided
7. Confirmed by the central laboratory as EGFR high expression.
8. Evaluable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
9. Ability to swallow drugs.
10. Adequate organ function.
11. Voluntarily join the study and sign informed consent ad has good compliance.

Exclusion Criteria:

1. Prior therapies with EGFR targeted drugs including EGFR antibodies.
2. Previously treated with Irinotecan and Tegafur.
3. Anthracycline, nitrosourea, and mitomycin within 6 weeks; traditional Chinese medicine for anti-tumor within 2 weeks;immune anti-tumor therapy. within 8 weeks;other anti-tumor therapies within 4 weeks before randomization.
4. Not recovered from adverse events due to a previously administered agent.
5. Have undergone major surgery within 4 weeks prior to randomization (not including diagnostic surgery) or expect major surgery during the study period.
6. Previously or currently participating in other clinical trials within 4 weeks before randomization (subjects who have entered the follow-up period are calculated based on the last use of experimental drugs or devices).
7. Received a live vaccine within 28 days before randomization or plan to receive live vaccine after enrollment.
8. Received a strong inducer or inhibitor of CYP3A4 enzyme within 1 week or received Solivudine or its structurally similar drugs within 56 days prior to randomization.
9. Simultaneously receiving any other anti-tumor treatment.
10. Has a known additional malignancy previously within the last 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or any other tumor that has been cured。
11. Central nervous system metastasis or uncontrolled central nervous system metastasis currently in need of treatment; or confirmed central nervous system metastasis, but not stable for more than 4 weeks after anti-tumor therapy; spinal cord compression, cancerous meningitis, or meningitis.
12. Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs.
13. Having active gastrointestinal ulcer, active gastrointestinal bleeding, and perforation;
14. Risk of major bleeding or esophageal fistula;
15. Previous or present with interstitial lung disease or immunotherapy-associated pneumonia; currently suffering from drug-induced pneumonia, radiation pneumonitis requiring steroid therapy, or clinically symptomatic active pneumonia, or other moderate to severe lungs that seriously affect lung function disease
16. Active infection during the screening period (including but not limited to infection requiring intravenous drip therapy), or unexplained fever (\> 38.5°C)within 2 weeks prior to randomization.
17. Has congenital or acquired immune deficiency (such as HIV infection).
18. Known active Hepatitis B or C.
19. Has any of the following diseases within the first 12 months of randomization: myocardial infarction, coronary artery bypass grafting or peripheral artery bypass graft surgery, heart failure (NYHA III to IV), etc and unstable angina with 6 months.
20. Has thrombosis or embolism occurred within the first 12 months of randomization, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, pulmonary embolism with heparin or other similar drugs.
21. QTc interval (QTcF) corrected by Fridericia method\> 470 ms; history of congenital long QT interval syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation) Or torsion-type ventricular tachycardia); left ventricular ejection fraction (LVEF) \<50%.
22. Allergies or contraindications to Z650 excipients (mannitol, sodium carboxymethyl starch, micronized silica gel, magnesium stearate, silicified microcrystalline cellulose), or to Irinotecan or Tegafur or its formulation ingredients.
23. Has uncontrolled pleural effusion, pericardial effusion, pelvic effusion, or ascites requiring repeated drainage.
24. Has a history of organ transplantation or a history of allogeneic bone marrow transplantation.
25. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of study medication.
26. Has other serious acute or chronic diseases and are not suitable for participating in clinical trials judged by investigators.

Where this trial is running

Beijing, Beijing Municipality

• Chinese PLA General Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Principal investigator: JianMing Xu, Doctor — Chinese PLA General Hospital
• Study coordinator: JianMing Xu, Doctor

Conditions Esophageal Cancer; ESCC; EGFR overexpression; Phase 3